[E-RFC (T cells) and Ig-positive cells (B cells) in the peripheral blood of patients with lymphogranulomatosis and possible immunocorrection with levamisole].
Forty patients with Hodgkin's disease were examined for cell-mediated immunity. Analysis of peripheral blood showed a decrease in the relative and absolute E-RFU counts depending on the disease stages. The changes in B-cells bearing surface immunoglobulins were negligible. E-RFC (T-cells) prevailed in the spleen of patients with Hodgkin's disease. However, some of the patients had a high enough count of B-cells in the spleen and peripheral blood. Multiple modality treatment for Hodgkin's disease, radiation therapy in particular, aggravated disorders of cell-mediated immunity. Thirty-one patients received levamisole at the definite stages of multiple modality treatment with a purpose of correcting cell-mediated immunity disorders. Two schemes of levamisole intake were tried. The drug was given in a dose of 150 mg for 21 days, the total dose amounting to 3, 150 mg, or in a dose of 150 mg for 4 days with a 10-day interval, the total dose being 2, 100 mg. Only two patients noted side effects one of them had a "gas taste" in the mouth, whereas the other one skin itch and urticaria that did not require any treatment. Application of levamisole increased the relative and absolute E-RFU counts, absolute lymphocyte count. Patients on levamisole noted the improvement of the well-being.
D000276:Adjuvants, Immunologic; D001402:B-Lymphocytes / Q000276:immunology*; D006689:Hodgkin Disease / Q000276:immunology*; D006801:Humans; D007958:Leukocyte Count; D007978:Levamisole / Q000627:therapeutic use; D008231:Lymphopenia / Q000188:drug therapy; D011947:Receptors, Antigen, B-Cell / Q000032:analysis*; D013154:Spleen / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology*
D000276:Adjuvants, Immunologic; D011947:Receptors, Antigen, B-Cell; D007978:Levamisole
E-ROK (T-kletki) i Ig-polozhitel'nye kletki (B-kletki) v perifericheskoĭ krovi bol'nykh limfogranulematozom i vozmozhnost' immunokorrektsii levamizolom.